Add To Watchlist
Share URL
About The Company
CEO
Mr. Michael F. Mahoney
Market Cap
98.97 Billion USD
Sector
Healthcare
Website
https://www.bostonscientific.comLast Update
2/22/2024, 12:00:00 PM
Description
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
Read More
Overview
Value
5
Growth
52
Health
56
Management
59
Analyst Opinion
89
Total
52
All Scores Out Of 100
Best Features
- Earnings growth has improved recently
- Has a low level of debt
- Low risk of bankruptcy
- Liked by analysts
- Has strong dividend growth
- Low preportion of income is paid as dividend
- Very safe dividend
Risk Factors
- Overvalued on cashflow basis
- There is a history of diluting shareholders
- No margin of safety at their current market price
- Disliked by Twitter users
- Price-to-earnings ratio of 62.8 is higher than the market average (19.6x)
- Accounting anomalies: Growing revenues without a corresponding growth in cash flows.
Market Peers
BSX
Key Figures
PE Ratio (TTM)
62.80
Margin Of Safety (DCF)
-72.35%
Revenue Growth (5 Year Average)
8.92%
Ratings Consensus
Strong Buy
Share Buybacks
-0.87%
Dividend Yeild (TTM)
0.03%
Valuation
Value Score
5
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: < 20.4 USD ✘
Current Price: 67.8 USD
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
62.80x
Free Cashflow Yeild
1.71%
PE/Earnings Growth
N/A
Price/Book
5.09x
Growth
Growth Score
52
- ✔ Revenue growth has improved this yeara
- ✔ 5 Year Average Earnings growth of 27.42% is higher than the market average (14.48%)
- ✔ Earnings growth has improved this year
- ✔ Free Cashflow growth has improved this year
- ✘ 5 Year Average Revenue growth of 8.92% is lower than the market average (10.97%)
- ✘ 5 Year Average Free Cashflow growth of -0.14% is lower than the market average (12.35%)
Revenue Growth
8.92%
Earnings Growth
27.42%
Cashflow Growth
-0.14%
Health
Health Score
56
Altman Z Score
4.51
Piostroski Score
7.00
Debt/Equity
0.51x
Current Assets/Liabilities
1.51x
Free Cashflow/Total Debt
0.10x
Debt/Capital
1.55x
Dividend
Secure Dividend Score
77
- ✔ Very safe
- ✔ Long term dividend payout ratio of -3.50% is considered good
- ✔ Payout ratio (TTM) of 1.76% is lower than the average (40%)
- ✔ Dividends have shown growth over the last 5 years
- ✘ Dividend yeild of 0.03% is less than the market average (1.85%)
- ✘ Dividend growth has been slowing recently
- ✘ Spending a higher percentage of their income on dividends than last 5 years
Dividend Yeild
0.03%
Dividend Growth
0.00%
Payout Ratio (Earnings)
1.76%
Payout Ratio (Cashflow)
1.64%
Management
Management Score
59
- ✔ Has issued new shares to finance growth when share price is high
- ✔ Has returned higher dividends when earnings have risen
- ✘ Return-on-capital-employed of 8.87% is lower than the market average (10%)
- ✘ Has a history of diluting shareholders to finance activity
- ✘ Return-on-equity of 4.09% is lower than the market average (15%)
Average Buybacks/Dilution
-0.87%
Recent Buybacks/Dilution
2.56%
5 Year Price Volitility
12.44%
Return On Assets
2.21%
Return On Capital Employed
8.87%
Return On Equity
4.09%
Return On Free Cashflow
N/A
Return On Investments
N/A
Analysts
Analyst Opinion
89
- ✔ Ratings consensus is Strong Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Boston Scientific Corporation
Currency
USD
Beta
0.796448
Vol Avg
8670050
Ceo
Mr. Michael F. Mahoney
Cik
0000885725
Cusip
101137107
Exchange
New York Stock Exchange
Full Time Employees
45000
Industry
Medical Devices
Sector
Healthcare
Ipo Date
1992-05-19
Address
300 Boston Scientific Way
City
Marlborough
State
MA
Country
US
Zip
01752-1234
Phone
508 683 4000
Analysis Last Updated
2/22/2024, 12:00:00 PM
All financial data provided by FMP
Social Sentiment
Social Sentiment Score
0
Twitter Sentiment
N/A
Stocktwits Sentiment
N/A